• S17:E4 – Morning Commute Podcast: FLT3 Treatment-Related Adverse Events in Patients with Acute Myeloid Leukemia

  • Nov 15 2023
  • Duración: 34 m
  • Podcast

S17:E4 – Morning Commute Podcast: FLT3 Treatment-Related Adverse Events in Patients with Acute Myeloid Leukemia

Escúchala gratis

Ver detalles del espectáculo

  • Resumen

  • FLT3-inhibitors, such as quizartinib, are changing the treatment paradigm for AML, in this podcast, our faculty take a look at the drug class, how they are used in AML, and how to manage any treatment-related adverse events.

    Visit www.morningcommutepodcast.com/aml4 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.
    Más Menos
Más Menos
activate_Holiday_promo_in_buybox_DT_T2

Lo que los oyentes dicen sobre S17:E4 – Morning Commute Podcast: FLT3 Treatment-Related Adverse Events in Patients with Acute Myeloid Leukemia

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.

Reseñas de Audible.com

Opiniones de Amazon
No hay comentarios disponibles